Prospective, Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase III Study with Orally Administered Budesonide for Prevention of Irinotecan (CPT-11)-Induced Diarrhea in Patients with Advanced Colorectal Cancer-Reference-Cited by-同舟云学术

Prospective, Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase III Study with Orally Administered Budesonide for Prevention of Irinotecan (CPT-11)-Induced Diarrhea in Patients with Advanced Colorectal Cancer

Published:2005 Issue:4-6 Volume:68 Page:326-332
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Karthaus M.,Ballo Harald,Abenhardt Wolgang,Steinmetz Tilmann,Geer Thomas,Schimke Jörg,Braumann Dietrich,Behrens Rüdiger,Behringer Dirk,Kindler Manfred,Messmann Helmut,Boeck Hans-Peter,Greinwald Roland,Kleeberg Ulrich

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference25 articles.

1. Lessons Learned from the Irinotecan Metabolic Pathway

2. Irinotecan Dosing: Does the CPT in CPT-11 Stand for “Can’t Predict Toxicity”?

3. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The beneficial effect of probiotics in the prevention of irinotecan-induced diarrhea in colorectal cancer patients with colostomy: a pooled analysis of two probiotic trials (Probio-SK-003 and Probio-SK-005) led by Slovak Cooperative Oncology Group;Frontiers in Oncology;2024-07-22

2. Managing Chemotherapy-Induced Diarrhea: Efficacy of Interventions for Cancer Patients;Biosciences Biotechnology Research Asia;2024-07-01

3. HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane;Breast Cancer Research and Treatment;2022-10-25

4. In vitro metabolic biomodulation of irinotecan to increase potency and reduce dose-limiting toxicity by inhibition of SN-38 glucuronide formation;Drug Metabolism and Personalized Therapy;2022-03-07

5. Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management;Toxicology Research;2021-05